Regulatory Framework & Implementation Strategy

REGULATORY DEFINITIONS & REQUIREMENTS

U.S. FDA (Food and Drug Administration)

Definition: “A systematic approach to evaluate, approve, and monitor suppliers based on their ability to consistently provide materials, components, or services that meet predetermined quality standards and regulatory requirements under current Good Manufacturing Practices (cGMP).”
Key Regulatory References:
• 21 CFR 211.84(d)(2-3): “Components, drug product containers, and closures shall be withheld from use until… released for use by the quality control unit. Each lot shall be tested or examined for conformity with written specifications.”
• 21 CFR 211.84(a): “Tests shall be conducted on each lot of drug product to determine conformity with specifications.”
• FDA Guidance for Industry: Quality Systems Approach to Pharmaceutical CGMP Regulations (2006): “The quality system model… includes management responsibilities, resources, manufacturing operations, and evaluation activities that encompass supplier qualification.”
Why Required: To ensure pharmaceutical components meet identity, strength, quality, and purity characteristics; prevent adulteration; and maintain product safety and efficacy throughout the supply chain.

Health Canada

Definition: “A documented system to assess, select, monitor, and approve suppliers ensuring all materials meet Food and Drugs Act requirements and are obtained from evaluated sources approved by the quality control department.”
Key Regulatory References:
• Food and Drug Regulations C.02.009/C.02.015: “Every fabricator… shall have a quality control department that approves or rejects raw materials and finished products.”
• C.02.011/C.02.019: “Raw materials and packaging materials must be purchased from an approved supplier.”
• GUI-0001: Good Manufacturing Practices (2009): “There should be written procedures describing the qualification and monitoring of suppliers.”
Why Required: To protect Canadian public health by ensuring pharmaceutical products contain only materials from qualified sources that consistently meet quality standards.

EU-GMP (European Medicines Agency)

Definition: “A formalized risk-based process to evaluate supplier suitability for providing goods/services impacting medicinal product quality, safety, or efficacy, often formalized through Quality Agreements.”
Key Regulatory References:
• EudraLex Volume 4, Part I, Chapter 5.26-5.31: “There should be written procedures for the selection of starting material suppliers… Suppliers should be approved by the Quality Department.”
• Chapter 7: Outsourced Activities: “The contract giver should assess the suitability of the contract acceptor… through audit.”
• Annex 16: Certification by a Qualified Person and Batch Release: “The QP must ensure suppliers are qualified.”
Why Required: To ensure patient safety and product efficacy within the EU market by maintaining control over the entire pharmaceutical supply chain.

WHO (World Health Organization)

Definition: “A documented procedure ensuring materials are purchased only from suppliers evaluated and approved by the quality unit based on demonstrated ability to meet specifications and GMP requirements.”
Key Regulatory References:
• WHO Technical Report Series, No. 996, Annex 2 (2016), Section 14: “Starting materials should be purchased only from approved suppliers.”
• WHO Technical Report Series, No. 1019, Annex 3 (2019): “The quality system should include control of suppliers.”
• WHO GMP for Pharmaceutical Products: Main Principles: “Suppliers should be evaluated and selected based on their ability to meet specifications.”
Why Required: To ensure global medicine quality, particularly for prequalification programs and supplies to resource-limited countries, through reliable supply chains.

 

SUPPLIER QUALIFICATION PROCESS

PHASE 1: INITIATION AND RISK-BASED PLANNING

The qualification process begins with a risk assessment to determine the appropriate level of supplier review. Materials and services are categorized by their potential impact on product quality and patient safety. Critical materials, such as APIs, sterile components, and primary packaging, receive the most rigorous scrutiny. High-risk items include solvents, colorants, and animal-derived ingredients due to contamination risks. Medium-risk items are excipients with secondary roles or secondary packaging, while low-risk materials include office and maintenance supplies. A risk scoring system evaluates factors like patient safety, product quality, regulatory significance, process complexity, supplier location, and performance history. The total score determines whether a supplier requires a document review, a detailed questionnaire, or a full on-site audit. This approach ensures efficient resource allocation while maintaining high-quality standards across the supply chain.

PHASE 2: COMPREHENSIVE EVALUATION AND ASSESSMENT

After a supplier is selected for qualification, they receive a comprehensive Supplier Questionnaire covering legal status, company structure, facility details, and regulatory history, including inspections by agencies such as the FDA, EMA, or Health Canada. The questionnaire also addresses the supplier’s Quality Management System, including document control, training, change management, deviation handling, and corrective actions. For technical review, suppliers provide GMP certificates, product specifications, test methods, stability data, and validation reports. API manufacturers must submit Drug Master Files or Certificates of Suitability, while packaging suppliers provide extractables and leachables studies. This document review establishes the supplier’s capabilities and compliance before any on-site evaluation. The audit team, typically composed of quality and technical experts, begins with an opening meeting to outline the audit scope and objectives. The facility tour assesses material flows, storage conditions, equipment maintenance, and housekeeping. Auditors then review key systems, focusing on quality control laboratories for data integrity, method validation, and investigation procedures. Production areas are evaluated for compliance with batch records, process controls, and cleaning validation. The audit includes interviews with staff at various levels to assess training effectiveness and commitment to quality. All findings are documented and classified as Critical, Major, or Minor based on their impact. A closing meeting presents these observations, and the supplier may clarify any points before the formal audit report is issued.

PHASE 3: PERFORMANCE QUALIFICATION AND SAMPLING

Following document review and audit, performance qualification verifies that materials consistently meet required standards. Several commercial-scale batches, typically one to three, are tested against full or agreed specifications. Results are compared to qualified materials or reference standards to ensure consistency. For APIs, emphasis is placed on impurity profiles, residual solvents, and polymorphic forms. Excipients may require additional testing beyond standard specifications. Packaging materials are assessed for compatibility and, if necessary, sterilization. The supplier’s stability data is reviewed, or a new stability monitoring plan is implemented for new materials. This phase confirms the supplier’s ability to reliably provide materials that meet quality requirements during routine use and storage.

PHASE 4: APPROVAL AND ONBOARDING

With satisfactory evaluation results, the supplier moves to formal approval. This stage centers on establishing a Quality Agreement, which is a legally binding document that clearly defines the responsibilities of both parties regarding quality standards, communication protocols, change notification procedures, audit rights, and complaint handling. The agreement specifies timelines for reporting changes and outlines dispute resolution mechanisms. Concurrently, a comprehensive Supplier Qualification Package is compiled, containing all documentation from previous phases: risk assessment, completed questionnaire, audit report, testing results, and stability data. This package undergoes rigorous review by a cross-functional team including quality assurance, procurement, supply chain, and technical services. Final approval is granted by the Head of Quality or designated Qualified Person, who bears regulatory responsibility for the decision. The supplier is then formally added to the Approved Supplier List, and their details are entered into the quality management system, enabling procurement to place orders.

PHASE 5: ONGOING MONITORING AND SUPPLIER REQUALIFICATION

A continuous process. Monitoring begins immediately after approval, tracking metrics such as material rejection rates, deviations, complaints, and delivery reliability. These metrics are reviewed regularly, often quarterly, and included in the Annual Product Quality Review. The relationship is managed through ongoing communication, quality checks, and periodic reviews. Formal requalification is scheduled, typically every two to three years for key suppliers, but may be adjusted based on performance. Requalification can range from a document review to a full audit, depending on risk and previous results. Additional audits may be required for significant supplier changes, recurring quality issues, or new regulations. This ongoing oversight ensures suppliers maintain quality standards and address issues promptly, safeguarding the supply chain over time.

 

GxP CELLATORS CONSULTANTS & THIRD-PARTY AUDITING

About GxP Cellators Consultants

We are independent experts who conduct supplier audits for pharmaceutical companies. We provide support when companies lack resources, specialized expertise, or require objective assessments.

Our Audit Services Cover:

• GMP Audits: Manufacturing facilities (APIs, finished products)
• GLP Audits: Laboratory testing facilities
• GCP Audits: Clinical trial sites and CROs
• GDP Audits: Distribution and storage facilities

Our Auditors Have Certifications:

• ISO Lead Auditor certifications
• ASQ Certified Quality Auditor
• Former regulatory inspectors (ex-FDA, ex-EMA)
• Technical specialists in sterile manufacturing, biologics, etc.

Benefits of Using Us:

• Objectivity: Independent view without internal bias
• Expertise: Specialized knowledge in specific areas
• Cost-Effective: Shared audits for multiple clients
• Global Reach: Auditors worldwide with local language skills
• Regulatory Insight: Knowledge of the latest requirements

How We Work:

• Understand the client’s specific needs.
• Develop a customized audit checklist.
• Conduct a thorough on-site assessment.
• Provide a detailed report with actionable findings.
• Follow up on corrective actions.
• Maintain confidentiality throughout

 

CONTACT INFORMATION

For professional supplier qualification services, please contact:
GxP Cellators Consultants
Email: